Skip to main content

Table 1 Characteristics in cohorts A and B according to bone involvement

From: Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer

CharacteristicCohort A Cohort B 
Non-squamous BoM+ (N/%)Non-squamous BoM- (N/%)pSquamous BoM+ (N/%)Squamous BoM- (N/%)p
Total patients626 (39)962 (61) 120 (32)251 (68) 
Median age (year/range)65 (29–89)67 (27–87)0.00167 (31–83)68 (31–91)0.06
Patients ≥75 years67 (11)165 (17)< 0.000118 (15)52 (21)0.19
Gender
 • Male401 (64)628 (65) 96 (80)202 (81)0.91
 • Female225 (36)334 (35)0.6224 (20)49 (19)
ECOG PS
 • 0213 (34)435 (45)< 0.000136 (30)98 (39)0.25
 • 1354 (56)461 (48)77 (64)138 (55)
 • 257 (9)51 (5)7 (6)15 (6)
 • Unk2 (1)15 (2)
Metastatic site
 • liver178 (28)149 (16)< 0.0000125 (21)38 (15)0.14
 • brain191 (30)218 (23)0.00116 (13)21 (8)0.17
Previous therapies
 • 1256 (41)359 (37)0.0754 (44)108 (43)0.67
 • 2176 (28)281 (29)37 (31)83 (33)
 • 3118 (19)162 (17)20 (17)48 (19)
 • > 374 (12)154 (16)9 (8)12 (5)
Smoking status
 • Never smoker134 (21)171 (18)0.0613 (11)18 (7)0.14
 • Former smoker308 (49)457 (48)69 (57)156 (62)
 • Active smoker134 (21)226 (23)23 (19)60 (24)
 • Unk50 (8)108 (11)15 (13)17 (7)
EGFR status
 • Mutated47 (8)55 (6)0.10   
 • Wild-type514 (82)779 (81)  
 • Unk65 (10)128 (13)  
KRAS status
 • Mutated91 (15)115 (12)0.23   
 • Wild-type132 (21)192 (20)  
 • Unk403 (64)655 (68)  
BRAF status
 • Mutated5 (1)6 (1)0.54   
 • Wild-type85 (14)114 (12)  
 • Unk536 (85)842 (87)  
ALK status
 • Mutated5 (1)11 (1)0.51   
 • Wild-type407 (65)645 (67)  
 • Unk214 (34)306 (32)  
ROS1 status
 • Mutated3 (1)1 (1)0.29   
 • Wild-type142 (23)207 (21)  
 • Unk481 (76)754 (78)  
  1. Unk Unknown